Figure 6.

Mefloquine (Mef) enhances the cytotoxicity of doxorubicin against colorectal cancer cells. A, B, HCT116 and RKO cells were treated with 500 nmol/L doxorubicin overnight in the presence or absence of 15 μmol/L mefloquine. The cells were assessed by (A) CCK‐8 assay for viability or (B) immunoblotting against PARP, p‐p65, p65, and GAPDH. C, D, HCT116 cells were transfected with siNC, siIKKβ#1 or siIKKβ#2 for 48 h and then treated with doxorubicin overnight. Cells were evaluated with the CCK‐8 assay for viability, and immunoblotting against IKKβ. GAPDH was used as a loading control. IKK, IκB kinase